Rasna Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended June 30, 2020
August 20, 2020 at 01:53 am IST
Share
Rasna Therapeutics, Inc. announced earnings results for the third quarter ended June 30, 2020. For the third quarter, the company announced operating loss was USD 92,564 compared to USD 191,845 a year ago. Net loss was USD 2.707 million compared to USD 209,543 a year ago. Basic loss per share from continuing operations was USD 0.04. For the nine months, operating loss was USD 423,425 compared to USD 854,463 a year ago. Net loss was USD 3.056 million compared to USD 876,207 a year ago. Basic loss per share from continuing operations was USD 0.04 compared to USD 0.01 a year ago.
Actavia Life Sciences, Inc. is a leukemia-focused biotechnology company. The Company is engaged in developing therapeutics to address the unmet need that exists for acute myeloid leukemia (AML), and other forms of leukemia and lymphoma. AML is generally a disease of older adults. It develops small molecule drug candidates targeting the LSD1 gene, which controls pathways underlying the etiology of AML subtypes. Its RASP-201 is a novel, orally dosed, selective reversible inhibitor of lysine specific demethylase (LSD1), a pathway that blocks differentiation and confers a poor prognosis to AML. RASP-201 when dosed orally shows in vivo therapeutic utility in murine (mouse) models of AML. Its primary indication is AML which may be fatal within weeks to months.
ACTAVIA LIFE SCIENCES, INC. 
